|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Fixed maturity securities available-for-sale, at estimated fair value (amortized cost: $85,466 and $85,907, respectively; allowance for credit losses of $63 and $62, respectively) | ||||||||||||||||||||
| Trading securities, at estimated fair value | ||||||||||||||||||||
| Equity securities, at estimated fair value | ||||||||||||||||||||
| Mortgage loans (net of allowance for credit losses of $220 and $200, respectively) | ||||||||||||||||||||
| Policy loans | ||||||||||||||||||||
| Limited partnerships and limited liability companies | ||||||||||||||||||||
| Short-term investments, principally at estimated fair value | ||||||||||||||||||||
| Other invested assets, principally at estimated fair value (net of allowance for credit losses of $0 and $0, respectively) | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Premiums, reinsurance and other receivables (net of allowance for credit losses of $3 and $3, respectively) | ||||||||||||||||||||
| Deferred policy acquisition costs and value of business acquired | ||||||||||||||||||||
| Current income tax recoverable | ||||||||||||||||||||
| Deferred income tax asset | ||||||||||||||||||||
| Market risk benefit assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Separate account assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Future policy benefits | ||||||||||||||||||||
| Policyholder account balances | ||||||||||||||||||||
| Market risk benefit liabilities | ||||||||||||||||||||
| Other policy-related balances | ||||||||||||||||||||
| Payables for collateral under securities loaned and other transactions | ||||||||||||||||||||
| Long-term and short-term debt | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Separate account liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Brighthouse Life Insurance Company’s stockholder’s equity: | ||||||||||||||||||||
| Common stock, par value $25,000 per share; 4,000 shares authorized; 3,000 shares issued and outstanding | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings (deficit) | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Total Brighthouse Life Insurance Company’s stockholder’s equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
